MedTrace Logo

T Cells Response to SARS COV 2 Peptides

NCT04573348 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2020-11-02

No results posted yet for this study

Summary

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations. The purpose of this study is to evaluate the T cells reactivity to SARS COV 2 immunogenic selected peptides by Metabolic Activity Method in convalesce and healthy individuals and to compare it with Antibody response (ELISA) and clinical information

Conditions

  • Covid19
  • Corona Virus Infection

Interventions

DIAGNOSTIC_TEST

Savicell's ImmunoBiopsy™

ImmunoBiopsy and ELISA

Sponsors & Collaborators

  • Savicell Diagnostics Ltd

    lead OTHER

Principal Investigators

  • Shafrira Shai, PhD · Savicell Diagnostics Ltd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2021-05-10
Completion
2021-10-10

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573348 on ClinicalTrials.gov